Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial.

Diabetol Metab Syndr · 2025 · PMC12801430 · PMID 41373013

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Given the relatively small subgroup sizes with borderline significant difference, these findings are considered hypothesis-generating warranting confirmation in larger studies.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.